Abstract
Adeno-associated viral (AAV) gene transfer of coagulation factor VIII and IX to skeletal muscle and liver of murine and canine models of hemophilia A and B have resulted in sustained systemic expression and, in several studies, in complete cure of the bleeding disorder. These impressive results prompted initiation of two Phase I/II clinical trials to evaluate the safety of AAV-factor IX gene transfer to muscle and liver of patients with severe hemophilia B. Herein, we have reviewed results from studies in animals with hemophilia, early experience with the vector system in the clinic, recent innovative approaches in vector design and delivery, and strategies to circumvent immunological limitations. Taken together, these studies provide much encouragement for the possibility of future clinical success, but also point out hurdles that still have to be overcome.
Keywords: coagulation factor, coagulation factor protein, gene-based therapy, canine hemophilia, missense mutations, murine f. transgene, hepatic gene transfer
Current Gene Therapy
Title: AAV-Mediated Gene Transfer for Treatment of Hemophilia
Volume: 5 Issue: 3
Author(s): Lixin Wang and Roland W. Herzog
Affiliation:
Keywords: coagulation factor, coagulation factor protein, gene-based therapy, canine hemophilia, missense mutations, murine f. transgene, hepatic gene transfer
Abstract: Adeno-associated viral (AAV) gene transfer of coagulation factor VIII and IX to skeletal muscle and liver of murine and canine models of hemophilia A and B have resulted in sustained systemic expression and, in several studies, in complete cure of the bleeding disorder. These impressive results prompted initiation of two Phase I/II clinical trials to evaluate the safety of AAV-factor IX gene transfer to muscle and liver of patients with severe hemophilia B. Herein, we have reviewed results from studies in animals with hemophilia, early experience with the vector system in the clinic, recent innovative approaches in vector design and delivery, and strategies to circumvent immunological limitations. Taken together, these studies provide much encouragement for the possibility of future clinical success, but also point out hurdles that still have to be overcome.
Export Options
About this article
Cite this article as:
Wang Lixin and Herzog W. Roland, AAV-Mediated Gene Transfer for Treatment of Hemophilia, Current Gene Therapy 2005; 5 (3) . https://dx.doi.org/10.2174/1566523054065048
DOI https://dx.doi.org/10.2174/1566523054065048 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?
Cardiovascular & Hematological Disorders-Drug Targets The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Haemodynamic Regulation of Gene Expression in Vascular Tissue Engineering
Current Vascular Pharmacology Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future
Current Pharmaceutical Design Antiplatelet and Anticoagulation Treatment in Patients with Thrombocytopenia
Current Pharmaceutical Design Discovery and Preliminary SAR of 5-Arylidene-2,2-Dimethyl-1,3-Dioxane- 4,6-Diones as Platelet Aggregation Inhibitors
Combinatorial Chemistry & High Throughput Screening Simultaneous Genotyping of Four Single Nucleotide Polymorphisms Associated with Risk Factors of Hemostasis Disorders
Combinatorial Chemistry & High Throughput Screening Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design ω-3 Polyunsaturated Fatty Acids Effects on the Cardiometabolic Syndrome and their Role in Cardiovascular Disease Prevention: An Update from the Recent Literature
Recent Advances in Cardiovascular Drug Discovery (Discontinued) The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design Novel Integrin-Specific Targets for Anti-Platelet Therapies
Current Pharmaceutical Design Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review
Reviews on Recent Clinical Trials <i>Achillea millefolium</i> E.Mey: Phytochemistry and Pharmacological Profile
Current Traditional Medicine Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
Current Vascular Pharmacology Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design Plasma Level of D-dimer is an Independent Diagnostic Biomarker for Deep Venous Thrombosis in Patients with Ischemic Stroke
Current Neurovascular Research